Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-Anisakis antibodies in colon cancer patients and their relationship with γδ T-cells.
Andreu-Ballester JC, Cuéllar C, Colmena-Zaragoza J, Galindo-Regal L, Hurtado-Marcos C, González-Fernández J, Balciscueta Z, García-Ballesteros C, López-Chuliá F, Jiménez AI, Llombart-Cussac A. Andreu-Ballester JC, et al. Parasitol Res. 2024 Apr 25;123(4):196. doi: 10.1007/s00436-024-08216-y. Parasitol Res. 2024. PMID: 38662084 Free PMC article.
Latent Microsporidia Infection Prevalence as a Risk Factor in Colon Cancer Patients.
Redondo F, Hurtado-Marcos C, Izquierdo F, Cuéllar C, Fenoy S, Sáez Y, Magnet Á, Galindo-Regal L, Uribe N, López-Bañeres M, Jiménez AI, Llombart-Cussac A, Del Águila C, Andreu-Ballester JC. Redondo F, et al. Cancers (Basel). 2022 Oct 29;14(21):5342. doi: 10.3390/cancers14215342. Cancers (Basel). 2022. PMID: 36358760 Free PMC article.
The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis.
Vaz Batista M, Pérez-García JM, Garrigós L, García-Sáenz JÁ, Cortez P, Racca F, Blanch S, Ruiz-Borrego M, Fernández-Ortega A, Fernández-Abad M, Iranzo V, Gion M, Martrat G, Alcalá-López D, Pérez-Escuredo J, Sampayo-Cordero M, Llombart-Cussac A, Braga S, Cortés J. Vaz Batista M, et al. Among authors: llombart cussac a. Med. 2024 Sep 4:S2666-6340(24)00312-X. doi: 10.1016/j.medj.2024.08.001. Online ahead of print. Med. 2024. PMID: 39265579
Moving toward response-adapted trials in oncology.
Pérez-García J, Antonarelli G, Gion M, Llombart-Cussac A, Cortés J. Pérez-García J, et al. Among authors: llombart cussac a. Nat Med. 2024 Nov 11. doi: 10.1038/s41591-024-03346-3. Online ahead of print. Nat Med. 2024. PMID: 39528666 No abstract available.
Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study.
Cortés A, López-Miranda E, Fernández-Ortega A, Carañana V, Servitja S, Urruticoechea A, Lema-Roso L, Márquez A, Lazaris A, Alcalá-López D, Mina L, Gener P, Rodríguez-Morató J, Antonarelli G, Llombart-Cussac A, Pérez-García J, Cortés J. Cortés A, et al. Among authors: llombart cussac a. Breast. 2024 Dec;78:103834. doi: 10.1016/j.breast.2024.103834. Epub 2024 Nov 3. Breast. 2024. PMID: 39520738 Free PMC article. Clinical Trial.
Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial.
Fullana B, Morales S, Petit A, Alay A, Verdaguer H, Climent F, Navarro-Perez V, Cejuela M, Galvan P, Gumà A, Llombart-Cussac A, Cordero D, Casanovas O, Prat A, Gil-Gil M, Pernas S. Fullana B, et al. Among authors: llombart cussac a. Sci Rep. 2024 Oct 9;14(1):23626. doi: 10.1038/s41598-024-72152-1. Sci Rep. 2024. PMID: 39384801 Free PMC article. Clinical Trial.
Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study.
Guerrero-Zotano Á, Pérez-García JM, Ruiz-Borrego M, Bermejo B, Gil-Gil M, de la Haba J, Alba Conejo E, Quiroga V, Carañana V, Urruticoechea A, Morales S, Bellet M, Antón A, Fernández-Abad M, Sánchez-Rovira P, Calabuig L, Pérez-Escuredo J, Sampayo-Cordero M, Cortés J, Llombart-Cussac A. Guerrero-Zotano Á, et al. Among authors: llombart cussac a. ESMO Open. 2024 Oct;9(10):103733. doi: 10.1016/j.esmoop.2024.103733. Epub 2024 Sep 30. ESMO Open. 2024. PMID: 39353215 Free PMC article.
High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer.
Quintela-Fandino M, Bermejo B, Zamora E, Moreno F, García-Saenz JÁ, Pernas S, Martínez-Jañez N, Jiménez D, Adrover E, de Andrés R, Mourón S, Bueno MJ, Manso L, Viñas G, Alba E, Llombart-Cussac A, Cortés J, Tebar C, Roe DJ, Grant A, Watson A, Colomer R, Mouneimne G. Quintela-Fandino M, et al. Among authors: llombart cussac a. Clin Cancer Res. 2024 Nov 15;30(22):5094-5104. doi: 10.1158/1078-0432.CCR-24-1518. Clin Cancer Res. 2024. PMID: 39283720 Clinical Trial.
Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial.
Vaz Batista M, Pérez-García JM, Cortez P, Garrigós L, Fernández-Abad M, Gion M, Martínez-Bueno A, Saavedra C, Teruel I, Fernandez-Ortega A, Servitja S, Ruiz-Borrego M, de la Haba-Rodríguez J, Martrat G, Pérez-Escuredo J, Alcalá-López D, Sampayo-Cordero M, Braga S, Cortés J, Llombart-Cussac A. Vaz Batista M, et al. Among authors: llombart cussac a. ESMO Open. 2024 Sep;9(9):103699. doi: 10.1016/j.esmoop.2024.103699. Epub 2024 Sep 9. ESMO Open. 2024. PMID: 39255534 Free PMC article. Clinical Trial.
141 results